Witnessing the stock’s movement on the chart, on Wednesday, Editas Medicine Inc (NASDAQ: EDIT) set off with pace as it heaved 0.51% to $1.99, before settling in for the price of $1.98 at the close. Taking a more long-term approach, EDIT posted a 52-week range of $1.97-$11.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 101.57% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 2.88%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -30.46%. This publicly-traded company’s shares outstanding now amounts to $82.54 million, simultaneously with a float of $81.77 million. The organization now has a market capitalization sitting at $164.28 million. At the time of writing, stock’s 50-day Moving Average stood at $2.9754, while the 200-day Moving Average is $4.9904.
Editas Medicine Inc (EDIT) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Editas Medicine Inc’s current insider ownership accounts for 0.94%, in contrast to 67.87% institutional ownership. According to the most recent insider trade that took place on Sep 04 ’24, this organization’s EVP, CHIEF MEDICAL OFFICER sold 518 shares at the rate of 3.42, making the entire transaction reach 1,774 in total value, affecting insider ownership by 133,895. Preceding that transaction, on Sep 04 ’24, Company’s CEO sold 1,555 for 3.42, making the whole transaction’s value amount to 5,325. This particular insider is now the holder of 313,724 in total.
Editas Medicine Inc (EDIT) Earnings and Revenue Records
Editas Medicine Inc’s EPS decrease for this current 12-month fiscal period is -30.46% and is forecasted to reach -2.25 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.70% through the next 5 years, which can be compared against the 2.88% growth it accomplished over the previous five years trading on the market.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Let’s observe the current performance indicators for Editas Medicine Inc (EDIT). It’s Quick Ratio in the last reported quarter now stands at 3.75. The Stock has managed to achieve an average true range (ATR) of 0.19. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.66.
In the same vein, EDIT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.56, a figure that is expected to reach -0.32 in the next quarter, and analysts are predicting that it will be -2.25 at the market close of one year from today.
Technical Analysis of Editas Medicine Inc (EDIT)
Going through the that latest performance of [Editas Medicine Inc, EDIT]. Its last 5-days volume of 2.1 million indicated improvement to the volume of 1.97 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 7.85% While, its Average True Range was 0.1719.
Raw Stochastic average of Editas Medicine Inc (EDIT) in the period of the previous 100 days is set at 0.98%, which indicates a major fall in contrast to 3.88% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 52.42% that was lower than 69.52% volatility it exhibited in the past 100-days period.
